OptimizeRx Corporation (OPRX) Q3 2025 Earnings Call Transcript
Q3 Revenue $26.1 million, an increase of 22% year-over-year from $21.3 million in Q3 2024. The increase is attributed to operational excellence, customer satisfaction, and deepened partnerships.
Adjusted EBITDA $5.1 million, an improvement of over $2 million from the same period last year. This reflects disciplined cost management and targeted cross-selling strategies.
Gross Margin 67.2%, up from 63.1% in Q3 2024. The improvement is due to a favorable product mix, economies of scale, and a favorable channel partner mix.
Operating Expenses $15.5 million, a decrease of $6.5 million year-over-year. The reduction is due to a $7.5 million impairment charge in Q3 2024, though cash OpEx increased due to higher bonus and commission payouts.
GAAP Net Income $0.8 million or $0.04 per share, compared to a GAAP net loss of $9.1 million or $0.50 per share in Q3 2024. This improvement reflects the company's strong performance.
Non-GAAP Net Income $3.9 million or $0.20 per share, compared to $2.3 million or $0.12 per share in Q3 2024. This reflects improved profitability.
Operating Cash Flow $11.6 million for the first 9 months of 2025, compared to a cash balance of $13.4 million on December 31, 2024. This indicates strong cash generation.
Term Loan Principal $28.8 million remaining at the end of Q3 2025, with an additional $2 million paid down post-quarter. Total principal paydown for the year is $7.5 million, reflecting accelerated debt reduction.
Average Revenue per Top 20 Pharmaceutical Manufacturer $3.1 million, up from $2.9 million in Q3 2024. This indicates stronger customer engagement.
Net Revenue Retention Rate 120%, showing strong customer retention and growth.
Revenue per FTE $820,000, up from $732,000 in Q3 2024, reflecting improved efficiency.
Get Free Real-Time Notifications for Any Stock
Analyst Views on OPRX
About OPRX
About the author
OptimizeRx Partners with Experian to Enhance DTC Marketing Effectiveness
- Data Integration Innovation: The collaboration between OptimizeRx and Experian integrates Micro-Neighborhood® audiences with Experian's identity graph, enabling life science brands to reach consumers more accurately, which is expected to significantly enhance the effectiveness of marketing campaigns.
- Audience Coverage Improvement: The new system reduces audience loss during the media onboarding process, which is projected to increase overall media reach, thereby enhancing brand influence in a competitive market.
- Precision Measurement Capability: By optimizing audience mapping, life science brands can measure exposed audiences more accurately, providing a more transparent view of engagement that will help brands optimize their marketing strategies and improve ROI.
- Privacy Safety Assurance: OptimizeRx's Micro-Neighborhood® audiences utilize privacy-compliant data, ensuring that consumer privacy needs are met while enhancing brands' marketing capabilities, further solidifying their leadership position in the healthcare technology sector.
OptimizeRx Expands POC Network with Four New Partner Agreements, Increasing NPI Reach by 37%
- Partnership Expansion: OptimizeRx has signed an exclusive multi-year agreement with a high-demand e-prescribing platform, significantly enhancing its in-workflow point-of-care network and fortifying its competitive position in the market.
- NPI Reach Increase: The addition of new partners boosts OptimizeRx's National Provider Identifier (NPI) reach by 37%, enabling clients to engage healthcare providers more effectively within clinical workflows.
- Renewal Strengthening: The company has renewed multi-year agreements with two top-performing electronic health record (EHR) and eRx platforms, one of which establishes an exclusive partnership, ensuring visibility into future channel revenue.
- Strategic Positioning: CEO Steve Silvestro stated that by deepening relationships with high-value partners, OptimizeRx is laying the groundwork for sustained profitable growth, addressing life sciences manufacturers' demand for in-workflow engagement.
